Liver Fibrosis Market Analysis, Size, Share & Growth Forecast 2026–2034

FibroScan Liver Stiffness Measurement kPa Correlating With F0 Below 7 Through Cirrhosis F4 Above 12.5 Has Established the Non-Invasive Fibrosis Staging Tool That Avoids the Biopsy Sampling Error, Procedural Risk, and Patient Refusal That Limit Histological Fibrosis Assessment.Madrigal Pharmaceuticals's MAESTRO-NASH data and March 2024 FDA approval at USD 47,400 annually established an access challenge for a condition affecting an estimated 1.5-6.5 million Americans with MASH F2-F3 fibrosis who meet treatment criteria, requiring payer prior-authorisation protocols that limit initial prescribing to hepatologists with liver biopsy-confirmed high-risk MASH. The biomarker strategy for MASH patient selection is evolving toward a combination of liver stiffness measurement by elastography, fibrosis-4 index, and MRI-PDFF fat quantification that reduces biopsy requirement while maintaining patient enrichment for those most likely to benefit from antifibrotic treatment. The MAESTRO-NASH OUTCOMES confirmatory trial is the commercially critical pending dataset in MASH drug development, as demonstration of reduced hard clinical endpoints including cirrhosis development and liver-related death is required to convert accelerated approval to traditional approval and sustain long-term payer reimbursement.

PRO-C3 Type III Collagen Formation Biomarker Measuring Active Fibrogenesis Rate Rather Than Cumulative Fibrosis Burden Provides the Dynamic Antifibrotic Treatment Response Marker That FibroScan Liver Stiffness Alone Cannot Distinguish From Established Scar Versus New Collagen Deposition.The mechanistic complementarity between resmetirom's hepatic mitochondrial beta-oxidation stimulation through THR-beta and semaglutide's adipose tissue mobilisation through GLP-1 receptor creates additive anti-steatotic and anti-inflammatory activity that is being tested in multiple combination Phase 2 trials. Madrigal's MAESTRO-COMBO trial combining resmetirom with semaglutide in MASH F2-F3 fibrosis is designed to test whether the combination achieves higher rates of MASH resolution and fibrosis improvement than either agent alone, with 52-week histological endpoints that would inform combination prescribing in a market where monotherapy rates are expected to plateau. The commercial rationale for combination positioning from Madrigal's perspective requires demonstrating that dual mechanism patients achieve superior outcomes that justify co-prescribing costs when both agents are commercially available at premium annual prices.

Antifibrotic Combination Rationale Targeting Resmetirom THR-Beta Hepatic Lipid Reduction, GLP-1 Adiposity Driver, and FXR Bile Acid Metabolism Simultaneously Is the Multi-Pathway Framework That NASH Fibrosis Heterogeneous Pathophysiology Requires Beyond the Single-Mechanism Approach.Akero Therapeutics's efruxifermin demonstrated 39% two-stage fibrosis improvement in Stage 2-4 MASH in HARMONY including compensated cirrhosis patients where FDA has acknowledged that fibrosis improvement in cirrhosis represents a clinically important regulatory endpoint. The FGF21 analogue mechanism of activating FGFR1/beta-klotho in hepatic stellate cells to induce quiescence and reduce collagen synthesis addresses the fibrotic component of MASH more directly than anti-steatotic mechanisms, positioning pegozafermin and efruxifermin as potentially more potent anti-fibrotic partners for combination with metabolic mechanisms in the severe fibrosis stages where hard clinical outcomes occur.

For related market intelligence, see the Nash Market.